Cargando…
Myosin in autoinhibited off state(s), stabilized by mavacamten, can be recruited via inotropic effectors
Mavacamten is a novel, FDA-approved, small molecule therapeutic designed to regulate cardiac function by selectively but reversibly inhibiting the enzymatic activity of myosin. It shifts myosin towards ordered off states close to the thick filament backbone. It remains unresolved whether mavacamten...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cold Spring Harbor Laboratory
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120679/ https://www.ncbi.nlm.nih.gov/pubmed/37090664 http://dx.doi.org/10.1101/2023.04.10.536292 |